Scientific Rationale

CP-201 and the parent compound are known to exhibit pleiotropic effects on cancer cells. There is good evidence indicating that the positive effects derive from an interaction with lipid rafts in the cell membranes which then lead to apoptosis of tumor cells.

  • The long carbon chain present in APLs is ideally suited to interact with the lipid rafts present in cell membranes
  • The modulation of lipid rafts affects cell signalling in many key pathways associated with apoptosis, or cell death
  • CP-201 is non-toxic, making it uniquely suitable for combination with other cancer therapeutics and radiotherapy
  • Lipid rafts are more prevalent in cancer cells than in normal cells

The modulation of lipid rafts both activates and inhibits key pathways associated with apoptosis / cell death

Activation of FAS and JNK pathways, and inhibition of the PI3K-Akt pathway, are all known to lead to apoptosis, or cell death.

Access to multiple pathways lower the risk of tumors developing resistance.

CP-201 and alkylphospholipids (APLS) specifically target cancer cells and leave normal cells unaffected

Human prostate cancer cells and normal human skin fibroblasts were co-cultured in presence of a fluorescent derivative of an APL analog.

The fluorescent APL (green) was taken up and accumulated only in the prostate cancer cells.

From: Sci Transl Med. 2014 June; 6(240)

The higher affinity for cancer cells over normal cells is a predictive indicator for a low rate of unwanted side effects during therapeutic anticancer use